Technical Analysis for COCP - Cocrystal Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
20 DMA Support | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Crossed Above 20 DMA | Bullish | -2.63% | |
Bollinger Band Squeeze | Range Contraction | -2.63% |
Alert | Time |
---|---|
20 DMA Support | about 23 hours ago |
10 DMA Support | about 23 hours ago |
Gap Up Closed | about 23 hours ago |
Gap Up Partially Closed | about 23 hours ago |
Outside Day | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 03/27/2024
Cocrystal Pharma, Inc. Description
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Coronavirus Influenza Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.285 |
52 Week Low | 1.325 |
Average Volume | 11,619 |
200-Day Moving Average | 2.02 |
50-Day Moving Average | 1.56 |
20-Day Moving Average | 1.48 |
10-Day Moving Average | 1.49 |
Average True Range | 0.10 |
RSI (14) | 46.81 |
ADX | 18.42 |
+DI | 13.43 |
-DI | 13.64 |
Chandelier Exit (Long, 3 ATRs) | 1.29 |
Chandelier Exit (Short, 3 ATRs) | 1.62 |
Upper Bollinger Bands | 1.54 |
Lower Bollinger Band | 1.41 |
Percent B (%b) | 0.53 |
BandWidth | 8.86 |
MACD Line | -0.02 |
MACD Signal Line | -0.03 |
MACD Histogram | 0.0069 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.65 | ||||
Resistance 3 (R3) | 1.65 | 1.61 | 1.62 | ||
Resistance 2 (R2) | 1.61 | 1.56 | 1.60 | 1.61 | |
Resistance 1 (R1) | 1.54 | 1.54 | 1.52 | 1.54 | 1.60 |
Pivot Point | 1.50 | 1.50 | 1.49 | 1.49 | 1.50 |
Support 1 (S1) | 1.43 | 1.45 | 1.41 | 1.43 | 1.36 |
Support 2 (S2) | 1.39 | 1.43 | 1.38 | 1.35 | |
Support 3 (S3) | 1.32 | 1.39 | 1.34 | ||
Support 4 (S4) | 1.32 |